4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis [PDF]
, 2019 A new series of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives were designed, synthesised, and evaluated to assess their inhibitory effect on the human monoamine oxidase (hMAO) A and B isoforms. Different (un)substituted (hetero)aromatic substituents
Alcaro, Stefano +10 more
core +1 more source
Deprenyl, an old drug with new anticancer potential: Mini review [PDF]
arXiv, 2021 The anticancer potential of monoamine oxidase (MAO) was observed in pre-clinical assays conducted with cell cultures and animals. L-Deprenyl (DEP) causes apoptosis in melanoma, leukemia and mammary cells. High-dose DEP has shown toxicity in mammary and pituitary cancers, as well as in monoblastic leukemia, in rats.
arxiv
Serotonergic and noradrenergic contributions to human motor cortical and spinal motoneuronal excitability [PDF]
arXiv, 2023 Animal models indicate that motor behaviour is shaped by monoamine neurotransmitters released diffusely throughout the brain and spinal cord. We present strong evidence that human motor pathways are equally affected by neuromodulation through noradrenergic and serotonergic projections arising from the brainstem.
arxiv
Medium dependence of asphaltene agglomeration inhibitor efficiency [PDF]
Energy & Fuels vol.22, 2008, pp 1917 - 1922;, 2007 Applying chemical additives (molecule inhibitors or dispersants) is one of the common ways to control asphaltene agglomeration and precipitation. However, it is not clear why at some conditions the synthetic flocculation inhibitors as well as resins not only do not inhibit the asphaltene agglomeration,, they may also promote it, and why the increasing ...
arxiv +1 more source
Meeting report : Neuropathology and Neuropharmacology of Monoaminergic systems [PDF]
, 2014 The third EU COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” Annual Conference entitled “Neuropathology and ...
De Deurwaerdere, Philippe +1 more
core +1 more source
Potential antidepressant effects of scutellaria baicalensis, hericium erinaceus and rhodiola rosea [PDF]
, 2020 Recent studies focused on the pharmacology and feasibility of herbal compounds as a potential strategy to target a variety of human diseases ranging from metabolic to brain disorders. Accordingly, bioactive ingredients which are found within a variety of
Biagioni, F +5 more
core +1 more source
The Prostate, 2019 Monoamine oxidase A (MAOA) is best known for its role in neuro‐transmitter regulation. Monoamine oxidase inhibitors are used to treat atypical depression.
S. Gaur +4 more
semanticscholar +1 more source
Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors. [PDF]
Int J Neuropsychopharmacol, 2015 Background: Monoamine oxidase inhibitors (MAOIs) are being developed for major depressive disorder, Alzheimer’s, and Parkinson’s Disease. Newer MAOIs have minimal sensitivity to tyramine, but a key limitation for optimizing their development is that ...
Chiuccariello L +10 more
europepmc +2 more sources
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]
, 2015 In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani +9 more
core +3 more sources
The multilayer connectome of Caenorhabditis elegans [PDF]
, 2016 Connectomics has focused primarily on the mapping of synaptic links in the brain; yet it is well established that extrasynaptic volume transmission, especially via monoamines and neuropeptides, is also critical to brain function. Here we present a draft monoamine connectome, along with a partial neuropeptide connectome, for the nematode C.
arxiv +1 more source